Nodal marginal zone B-cell lymphoma

3 trials MedDRA PT
3 Registered trials
0 Recruiting
3 Unique sponsors
4 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
L Oncology (ATC L) 2
Mechanism of action (INN-stem analysis)
CAR-T cell therapy 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Unknown / small molecule 1 substance
Monoclonal antibody (chimeric) 1 substance
Phase II: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

3 trials
  • Celgene Corp. Commercial
    LISOCABTAGENE MARALEUCEL
    2024-510966-18-00 6 countries 2024 n=99 Orphan
    Ended
  • Universitaetsklinikum Ulm AöR Academic
    OBINUTUZUMAB
    2024-517476-38-00 1 country 2018 n=56
    Ended
  • University Hospital Of Ulm AöR Academic
    COPANLISIB DIHYDROCHLORIDE; RITUXIMAB
    2022-500674-34-00 1 country 2019 n=36
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Celgene Corp. Commercial 1 Phase II 0
Universitaetsklinikum Ulm AöR Academic 1 Phase II 0
University Hospital Of Ulm AöR Academic 1 Phase II 0
New trials by year
2019
1
2024
1
← All indication landscapes